Core Insights - Rep. Marjorie Taylor Greene purchased shares of Netflix Inc. on October 24, following a significant drop in the stock price after a disappointing third-quarter earnings report [1][2] Investment Activity - The purchase of Netflix was valued between $1,001 and $15,000 and was part of 14 new investments disclosed in a Periodic Transaction Report filed on October 28 [2][5] - Greene's investment strategy appears to align with a "buy the dip" approach, as she made the purchase shortly after the stock's decline [2] - This transaction adds to her existing position in Netflix, which she had previously purchased in June and May [3] Broader Investment Strategy - Greene's investment in Netflix is part of a larger trend of increasing her holdings in the technology sector, including purchases in Microsoft Corp., Amazon.com Inc., and MercadoLibre Inc. [3] - She has also continued to build her position in the iShares Bitcoin Trust ETF, indicating a consistent strategy of adding to existing holdings [4] - Other notable purchases in October included investments in finance (Berkshire Hathaway Inc., Blackstone Inc.), healthcare (Amgen Inc., Cardinal Health Inc.), and energy (Chevron Corp.) [5][6] Summary of Transactions - A total of 14 transactions were reported, all of which were purchases valued between $1,001 and $15,000, with no sales reported [5][6]

Core Insights - Analysts project Amgen (AMGN) will report quarterly earnings of $5.00 per share, reflecting a 10.4% decline year over year, with revenues expected to reach $8.94 billion, a 5.2% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.9% over the past 30 days, indicating a reassessment by covering analysts [1][2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2] Revenue Projections - Analysts estimate 'Revenue- Other revenues' at $373.34 million, indicating a year-over-year change of +6.1% [4] - 'Revenue- Product sales' is projected to be $8.55 billion, reflecting a +4.8% change from the prior-year quarter [4] Product Sales Forecasts - 'Product Sales- BLINCYTO- Total' is expected to reach $412.70 million, showing a +26.2% change year over year [4] - 'Product Sales- Otezla- Total' is forecasted at $582.08 million, indicating a +3.2% change [5] - 'Product Sales- Neulasta- U.S.' is expected to be $60.90 million, reflecting a -27.5% change [5] - 'Product Sales- Repatha- U.S.' is projected at $367.86 million, indicating a +30.9% change [6] - 'Product Sales- BLINCYTO- U.S.' is expected to reach $298.45 million, reflecting a +25.9% change [7] Market Performance - Amgen shares have shown a return of -2.3% over the past month, compared to a +3.6% change in the Zacks S&P 500 composite [8]

Core Viewpoint - Celltrion, Inc. has received FDA designation for its biosimilars STOBOCLO® and OSENVELT® as interchangeable with the reference products PROLIA® and XGEVA®, respectively, for all approved indications, enhancing patient access and treatment options in the U.S. market [1][5]. Group 1: Product Information - STOBOCLO® (denosumab-bmwo) is indicated for treating postmenopausal women with osteoporosis at high risk for fracture, increasing bone mass in men with osteoporosis, and treating glucocorticoid-induced osteoporosis [4][6]. - OSENVELT® (denosumab-bmwo) is indicated for preventing skeletal-related events in patients with multiple myeloma and bone metastases, treating unresectable giant cell tumor of bone, and managing hypercalcemia of malignancy [17][21]. Group 2: Regulatory Designation - The FDA's interchangeability designation allows STOBOCLO and OSENVELT to be substituted for their reference products at pharmacies without consulting the prescriber, subject to state laws [3][5]. - The designations were based on comprehensive clinical data, including Phase III trial results demonstrating efficacy, safety, and pharmacokinetics in postmenopausal women with osteoporosis [3][5]. Group 3: Market Impact - The interchangeability designations are expected to reinforce confidence among healthcare providers, facilitating a smoother transition to these biosimilars and potentially leading to cost savings for patients and the U.S. healthcare system [3][5]. - STOBOCLO and OSENVELT were introduced to the U.S. market in July 2025, with STOBOCLO available in a 60 mg/mL injection and OSENVELT in a 120 mg/1.7 mL (70 mg/mL) injection [3][4].

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's seni ...

Core Insights - Amgen (AMGN) is set to report its third-quarter 2025 results on November 4, with earnings expected to be $5.00 per share and sales at $8.94 billion, reflecting a 14.5% earnings surprise in the last quarter [1][9] Sales Performance - Strong volume growth from products like Evenity, Repatha, and Blincyto is anticipated to drive sales, with consensus estimates for these products at $519 million, $720 million, and $413 million respectively [2] - The company's own estimates for Evenity, Repatha, and Blincyto are slightly lower at $463.9 million, $672.2 million, and $395.5 million respectively [3] - Sales of RANKL antibodies, Prolia, and Xgeva are expected to decline significantly due to patent expirations and the launch of three biosimilars in the U.S. market [4] New Product Contributions - Newer drugs such as Imdelltra, Tavneos, and Tezspire are projected to contribute positively to top-line growth, with consensus estimates for Tezspire and Tavneos at $364 million and $119 million respectively [5] - The company's estimates for Tezspire and Tavneos are $270.6 million and $120.7 million respectively [5] Competitive Pressures - Kyprolis is expected to face continued competitive pressure, with consensus sales estimates at $374 million and the company's estimate at $372.6 million [6] - Enbrel sales are likely to decline due to price reductions, while Otezla is expected to benefit from volume growth, with consensus estimates for Otezla at $582 million and Enbrel at $645 million [6] Recent Acquisitions - Sales of rare disease drugs Tepezza, Krystexxa, and Uplizna, acquired from Horizon in October 2023, showed improvement in the second quarter and are expected to continue this trend [7] Biosimilar Market Impact - Lower revenues from oncology biosimilars and legacy products are anticipated, although newer biosimilars like Wezlana and Pavblu may contribute to sales growth [8][10] Financial Outlook - Higher R&D costs are likely to impact operating margins negatively in the third quarter [11] - Amgen's earnings surprise history shows a strong performance, with an average surprise of 11.75% over the last four quarters [12] Earnings Prediction - The current Earnings ESP for Amgen is -1.25%, indicating uncertainty regarding an earnings beat this quarter [14]

Summary of Key Points from the Conference Call on China's Healthcare Industry and Emerging Oral GLP-1 Pipelines Industry Overview - The report focuses on the **emerging oral GLP-1 pipeline** within the **China healthcare industry** and discusses the potential market size exceeding **$45 billion** [1][8][14]. Core Insights and Arguments - The global oral GLP-1 market is projected to peak between **$45 billion and $75 billion**. Recent clinical data from leading companies indicate that emerging pipelines still have opportunities for market entry [8][14]. - Over **20 oral GLP-1 candidates** from Chinese biopharmaceutical companies are in development, with most retaining global rights. This suggests significant potential for future licensing and partnerships [8][18]. - Companies such as **Hengrui/Kailera**, **Huadong Medicine**, and **Regor Therapeutics** are leading in clinical progress and data maturity, with several key catalytic events expected in the next six months [8][18]. - The emerging pipeline is diverse, including candidates from **Hansoh Pharmaceutical**, **China Biologic Products**, **Sino Biopharma**, and several private companies [8][18]. - Variations in patient baseline characteristics and dose escalation strategies complicate direct data comparisons across clinical trials. Other critical factors include data integrity for indications beyond obesity, scalability of production, and patent reviews [8][18]. Additional Important Insights - The oral GLP-1 market is evolving towards a more fragmented competitive landscape, contrary to the previously expected oligopolistic structure. Recent clinical results from leading candidates suggest new entry opportunities for emerging pipelines [15][18]. - The report outlines the competitive landscape and potential collaboration opportunities, highlighting that the U.S. biopharma sector is actively seeking partnerships with Chinese companies due to the evolving market dynamics [18][20]. - The report includes a detailed table of oral GLP-1 candidates, their development phases, and licensing status, providing a comprehensive overview of the competitive landscape [3][20]. Conclusion - The oral GLP-1 market presents a significant opportunity for both established and emerging players, particularly from China. The evolving clinical data and competitive dynamics suggest a promising future for innovative therapies in this space [8][14][15].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Amgen Inc. [1] Group 1 - The investigation pertains to whether Amgen's leadership acted in the best interests of shareholders [1] - Shareholders who acquired Amgen stock on or before July 29, 2020, may seek various forms of corporate governance reforms and financial relief [1]

Incident at Hong Kong International Airport - A cargo plane operated by Turkish carrier Air ACT skidded off the North Runway at Hong Kong International Airport, resulting in one ground staff fatality and another critically injured [2][3][8] - The North Runway is currently closed for investigation and safety inspections, while other runways remain operational [3][8] FAA Flight Delays - The Federal Aviation Administration reported widespread flight delays at major U.S. airports, including Dallas, Chicago, and Newark, due to air traffic control staffing issues exacerbated by a government shutdown [4][8] - The U.S. Travel Association estimates that the ongoing shutdown could cost the economy $1 billion per week [4] Biopharmaceutical Sector Update - Amgen announced positive topline results from its Phase 3 FORTITUDE-101 clinical trial for bemarituzumab, showing a statistically significant improvement in overall survival for patients with advanced gastric cancer [5][8] - Detailed efficacy and safety data from the trial are expected to be presented at an upcoming medical congress [5] Market Sentiment - S&P 500 E-mini futures rose 0.2% and Nasdaq futures were up 0.3% in early Asian trading, following a higher close on Wall Street [6][8] - Positive market sentiment is attributed to President Trump's actions to ease trade tensions with China and the stabilization of regional bank shares [6][8] - The market is pricing in a 100% chance of a 25 basis point rate cut at the upcoming Federal Open Market Committee meeting [6]

Core Insights - AstraZeneca and Amgen's TEZSPIRE® has received approval in the US for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and older [1] - TEZSPIRE is the first and only biologic targeting thymic stromal lymphopoietin (TSLP) approved for CRSwNP, indicating a significant advancement in treatment options for this condition [1] Company Summary - The approval by the US Food and Drug Administration (FDA) marks a milestone for AstraZeneca and Amgen in expanding their product offerings in the field of chronic inflammatory diseases [1] - TEZSPIRE's unique mechanism of action targeting TSLP positions it as a pioneering treatment in the biologics market for CRSwNP [1]

Core Insights - The U.S. Food and Drug Administration has approved a new drug developed by Amgen and AstraZeneca for treating a type of chronic sinus infection [1] Company Summary - Amgen and AstraZeneca are the drugmakers behind the newly approved treatment for chronic sinus infections [1]